Trial Profile
Clinical Study Evaluating Safety and Efficacy of a Nepafenac Punctal Plug Delivery System (N-PPDS) Compared With Placebo Punctal Plug Delivery System (p-PPDS) in Controlling Post-Operative Ocular Pain and Inflammation After Routine Unilateral Cataract Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Nepafenac (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Mati Therapeutics
- 08 Feb 2021 Primary endpoint (Assessment of pain: Nepafenac group compared to the placebo group) has been met, according to a Mati Therapeutics media release.
- 08 Feb 2021 According to a Mati Therapeutics media release, results from this study has been published in the February Journal of Cataract and Refractive Surgery.
- 08 Feb 2021 Results presented in a Mati Therapeutics media release.